Peer-influenced content. Sources you trust. No registration required. This is HCN.

Medical Professionals Reference (MPR)Wegovy Labeling Updated With Additional Option for Maintenance Dosing

Wegovy is a glucagon-like peptide-1 receptor agonist.

The updated prescribing information for Wegovy (semaglutide) now includes new guidelines for maintenance dosing in adults and pediatric patients. This change is based on a recent study and offers more flexibility in dosing options for adults, while pediatric dosing remains unchanged.

Key Points:

  • Wegovy is used for chronic weight management in adults and pediatric patients with specific BMI criteria.
  • The maintenance dosage for adults can now be either 2.4mg (recommended) or 1.7mg once weekly.
  • The update was informed by a study involving 401 East Asian patients, showing significant weight reduction with both 1.7mg and 2.4mg doses.
  • Previously, the labeling required discontinuation in adults unable to tolerate 2.4mg; this has been removed, and 1.7mg has been added as an option.

Additional Points:

  • Pediatric maintenance dosage remains at 2.4mg once weekly.
  • Treatment response and tolerability are key factors in selecting the maintenance dosage.


  • The updated guidelines provide more flexibility in adult maintenance dosing, reflecting the latest research findings, while pediatric guidelines remain consistent.

Related Posts

Additional Info
US Food and Drug Administration. Wegovy supplement approval letter.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form